Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach